Prospera Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Prospera Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $412.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Prospera Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $412.0K Trade | TransData Nexus

Prospera Life Sciences Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $412.0K Total Trade · DGFT Verified

Prospera Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $412.0K across 6 products in 2 therapeutic categories. Based on 139 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Lenvatinib ($115.1K), Sofosbuvir ($94.3K), Velpatasvir ($88.8K).

Prospera Life Sciences Private Limited — Export Portfolio & Destination Treemap

Prospera Life Sciences Private Limited pharmaceutical export portfolio — 6 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Prospera Life Sciences Private Limited? — Company Overview & Market Position

Prospera Life Sciences Private Limited is a pharmaceutical company incorporated on September 29, 2022, in Gurgaon, Haryana, India. The company is registered under the Corporate Identification Number (CIN) U24290HR2022PTC106894 and is classified as a private limited company limited by shares. Its authorized and paid-up capital stands at ₹1,000,000 each.

The registered office is located at H No. 400/12, Jacumpura, Near Dr. Jai Bhagwan, Gurgaon, Haryana, 122001. The company is unlisted and operates in the pharmaceutical sector, focusing on the manufacture of chemical products.

As of April 8, 2024, Prospera Life Sciences Private Limited reported zero employees, indicating that it may be in the early stages of its operational phase.

What Does Prospera Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Lenvatinib$115.1K 2Sofosbuvir

Product Portfolio — Top 6 by Export Value

Prospera Life Sciences Private Limited exports 6 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Lenvatinib	Advanced Oncology	$115.1K	42	5.4%	3
2	Sofosbuvir	Antiviral & HIV Medications	$94.3K	21	0.2%	12
3	Velpatasvir	Antiviral & HIV Medications	$88.8K	15	0.4%	9
4	Sorafenib	Advanced Oncology	$62.8K	29	0.4%	7
5	Gefitinib	Advanced Oncology	$47.4K	26	0.7%	6
6	Cabozantinib	Advanced Oncology	$3.6K	6	2.8%	9

Prospera Life Sciences Private Limited exports 6 pharmaceutical products across 2 therapeutic categories with a total export value of $412.0K. The top category is Advanced Oncology (55.6% of portfolio), followed by Antiviral & HIV Medications (44.4%), indicating a concentrated portfolio with the top 5 products accounting for 99.1% of total export value.

Prospera Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

As of April 8, 2024, Prospera Life Sciences Private Limited reported zero employees, indicating that it may be in the early stages of its operational phase.

2Manufacturing Facilities

Specific details regarding the manufacturing facilities of Prospera Life Sciences Private Limited are not publicly available. The company's registered address in Gurgaon, Haryana, suggests that its operations are based in this region. However, without explicit information on plant locations, capacities, or specializations, a comprehensive assessment of its manufacturing capabilities cannot be provided.

3Key Leadership

The company's leadership comprises two directors:

Nishant Sharma: Director since September 29, 2022.
Ankush: Director since September 29, 2022.

No additional information regarding other key executives or their roles is available from the provided sources.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Prospera Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Prospera Life Sciences Private Limited's export activities, as reported by TransData Nexus, indicate a total export value of $412,000 USD across 139 shipments from 2022 to 2026. The company's product portfolio includes six finished pharmaceutical formulations across two therapeutic categories: Advanced Oncology (55.6%) and Antiviral & HIV Medications (44.4%). The top five exported products are:

Lenvatinib: $115,000 USD, Rank #3, 5.4% market share.
Sofosbuvir: $94,000 USD, Rank #12, 0.2% market share.
Velpatasvir: $89,000 USD, Rank #9, 0.4% market share.
Sorafenib: $63,000 USD, Rank #7, 0.4% market share.
Gefitinib: $47,000 USD, Rank #6, 0.7% market share.

The company's export activities primarily target markets in Southeast Asia, including Thailand, Laos, Singapore, Cambodia, and Malaysia. Notably, in 2025, the company exported approximately $495,000 USD worth of products to Thailand and $575,000 USD to Laos.

Emerging Markets

Prospera Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Prospera Life Sciences Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no current market access in the U.S. Without explicit regulatory filings or approvals, a detailed assessment of the company's FDA status cannot be provided.

2WHO & EU GMP

Information regarding Prospera Life Sciences Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not available from the provided sources. Given the company's focus on Southeast Asian markets, obtaining WHO prequalification could enhance its credibility and facilitate market access. However, without specific certifications, the company's standing in this regard remains unclear.

3CDSCO & Indian Regulatory

Prospera Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Southeast Asian pharmaceutical market, Prospera Life Sciences Private Limited faces competition from both local and international companies. While specific competitors are not identified in the provided sources, the company's focus on advanced oncology and antiviral medications places it in competition with other pharmaceutical firms offering similar products. The company's export data indicates a significant presence in Thailand and Laos, suggesting a competitive position in these markets. However, without detailed market share data, a comprehensive competitive analysis cannot be conducted.

2Key Differentiators

Prospera Life Sciences Private Limited's product portfolio, which includes advanced oncology and antiviral medications, positions it to address critical healthcare needs in emerging markets. The company's export data indicates a growing presence in Southeast Asia, reflecting successful market penetration strategies. However, the company's reliance on a limited number of products and markets may pose challenges in terms of diversification and risk management.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Prospera Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Prospera Life Sciences Private Limited's export data indicates a consistent volume of shipments, primarily to Southeast Asian markets. The company's focus on finished pharmaceutical formulations suggests a commitment to quality and compliance with international standards. However, the absence of detailed information regarding manufacturing facilities, certifications, and regulatory approvals limits a comprehensive assessment of the company's reliability as a supplier.

2Certifications to Verify

Importers considering Prospera Life Sciences Private Limited as a supplier should verify the following certifications:

FDA Facility Registration: Confirm the company's registration with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.
WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards to ensure product quality.
EU GMP Certification: Confirm compliance with European Union Good Manufacturing Practice standards for market access in EU countries.

Frequently Asked Questions — Prospera Life Sciences Private Limited

How many pharmaceutical products does Prospera Life Sciences Private Limited export from India?

Prospera Life Sciences Private Limited exports 6 pharmaceutical products across 2 therapeutic categories. The top exports are Lenvatinib ($115.1K), Sofosbuvir ($94.3K), Velpatasvir ($88.8K), Sorafenib ($62.8K), Gefitinib ($47.4K). Total export value is $412.0K.

What is Prospera Life Sciences Private Limited's total pharmaceutical export value?

Prospera Life Sciences Private Limited's total pharmaceutical export value is $412.0K, based on 139 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Prospera Life Sciences Private Limited cover?

Prospera Life Sciences Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (55.6%, 4 products), Antiviral & HIV Medications (44.4%, 2 products).

Get Full Prospera Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.